This Week In Space podcast: Episode 165 — Guardians of Space
When you buy through links on our articles, Future and its syndication partners may earn a commission.
On Episode 165 of This Week In Space, Rod Pyle and Tariq Malik talk with NASA astronaut Nick Hague, the first U.S. Space Force Guardian to launch to the International Space Station in that role.
Space is rapidly becoming a critical domain for so much of 21st-century living. Banking, transport across the sea and land, agriculture, and dozens of other things we take for granted all depend on satellites, and tracking them to avoid collisions.
We invited Hague to talk to us about the Space Force, living on the ISS, his frightening abort on a Soyuz rocket in 2018, how the Space Force tracks orbital objects, and much more. He's a very accomplished guy who makes it all sound routine — and we suspect, for him, it is. Join us for this very special interview.
Download or subscribe to this show at: https://twit.tv/shows/this-week-in-space.Get episodes ad-free with Club TWiT at https://twit.tv/clubtwit
European Space Agency reveals 3 key space missions threatened by Trump's NASA budget cuts
Trump's 2026 budget cuts would force the world's most powerful solar telescope to close
Humanity takes its 1st look at the sun's poles: 'This is just the first step of Solar Orbiter's stairway to heaven'
Wanted: One NASA administrator
Nick Hague
Space Force
Space Force Guardian returns to Earth after six-month space mission
Why Cislunar Security Must Be a Space Force Concern
How do Astronauts Sleep on Space?
TOP TELESCOPE PICK:
Looking for a telescope to see planets and comets? We recommend the Celestron Astro Fi 102 as the top pick in our best beginner's telescope guide.
Finally, did you know you can launch your own SpaceX rocket? Model rocket maker Estes' stunning scale model of a Falcon 9 rocket that you can pick up now. The launchable model is a detailed recreation of the Falcon 9 and retails for $149.99. You can save 10% by using the code IN-COLLECTSPACE at checkout, courtesy of our partners collectSPACE.com.
This Week in Space covers the new space age. Every Friday we take a deep dive into a fascinating topic. What's happening with the new race to the moon and other planets? When will SpaceX really send people to Mars?
Join Rod Pyle and Tariq Malik from Space.com as they tackle those questions and more each week on Friday afternoons. You can subscribe today on your favorite podcatcher.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Trump and TSMC pitched $1 trillion AI complex — SoftBank founder Masayoshi Son wants to turn Arizona into the next Shenzhen
When you buy through links on our articles, Future and its syndication partners may earn a commission. Masayoshi Son, founder of SoftBank Group, is working on plans to develop a giant AI and manufacturing industrial hub in Arizona, potentially costing up to $1 trillion if it reaches full scale, reports Bloomberg. The concept of what is internally called Project Crystal Land involves creating a complex for building artificial intelligence systems and robotics. Son has talked to TSMC, Samsung, and the Trump administration about the project. Masayoshi Son's Project Crystal Land aims to replicate the scale and integration of China's Shenzhen by establishing a high-tech hub focused on manufacturing AI-powered industrial robots and advancing artificial intelligence technologies. The site would host factories operated by SoftBank-backed startups specializing in automation and robotics, Vision Fund portfolio companies (such as Agile Robots SE), and potentially involve major tech partners like TSMC and Samsung. If fully realized, the project could cost up to $1 trillion and is intended to position the U.S. as a leading center for AI and high-tech manufacturing. SoftBank is looking to include TSMC in the initiative, given its role in fabricating Nvidia's AI processors. However, a Bloomberg source familiar with TSMC's internal thinking indicated that the company's current plan to invest $165 billion in total in its U.S. projects has no relation to SoftBank's projects. Samsung Electronics has also been approached about participating, the report says. Talks have been held with government officials to explore tax incentives for companies investing in the manufacturing hub. This includes communication with Commerce Secretary Howard Lutnick, according to Bloomberg. SoftBank is reportedly seeking support at both the federal and state levels, which could be crucial to the success of the project. The development is still in the early stages, and feasibility will depend on private sector interest and political support, sources familiar with SoftBank's plans told Bloomberg. To finance its Project Crystal Land, SoftBank is considering project-based financing structures typically used in large infrastructure developments like pipelines. This approach would enable fundraising on a per-project basis and reduce the amount of upfront capital required from SoftBank itself. A similar model is being explored for the Stargate AI data center initiative, which SoftBank is jointly pursuing with OpenAI, Oracle, and Abu Dhabi's MGX. Melissa Otto of Visible Alpha suggested in a Bloomberg interview that rather than spending heavily, Son might more efficiently support his AI project by fostering partnerships between manufacturers, AI engineers, and specialists in fields like medicine and robotics, and by backing smaller startups. However, she notes that investing in data centers could also reduce AI development costs and drive wider adoption, which would be good for the long term for AI in general and Crystal Land specifically. Nonetheless, it is still too early to judge the outcome. The rumor about the Crystal Land project has emerged as SoftBank is expanding its investments in AI on an already large scale. The company is preparing a $30 billion investment in OpenAI and a $6.5 billion acquisition of Ampere Computing, a cloud-native CPU company. While these initiatives are actively developing, the pace of fundraising for the Stargate infrastructure has been slower than initially expected. SoftBank's liquidity at the end of March stood at approximately ¥3.4 trillion ($23 billion). To increase available funds, the company recently sold about a quarter of its T-Mobile U.S. stake, raising $4.8 billion. It also holds ¥25.7 trillion ($176.46 billion) in net assets, the largest portion of which is in chip designer Arm Holdings. Such vast resources provide SoftBank with room to secure additional financing if necessary, Bloomberg notes Follow Tom's Hardware on Google News to get our up-to-date news, analysis, and reviews in your feeds. Make sure to click the Follow button.
Yahoo
11 minutes ago
- Yahoo
Investors should consider this growth stock… it's SpaceX's competition
Rocket Lab (NASDAQ:RKLB) is a US-listed growth stock that gives investors rare access to the commercial space sector. As a vertically integrated launch and space systems provider, Rocket Lab is often compared to SpaceX in its ambition and capabilities. But there's one crucial difference: you can actually buy shares in Rocket Lab, while SpaceX remains private. Rocket Lab delivers launch services, builds small and medium-class rockets, and manufactures spacecraft components for a range of commercial, government, and defense customers. With rapid revenue growth, an impressive order book, and expansion into new markets, Rocket Lab offers public market investors a way to participate in the booming space economy. It targets many of the same opportunities as its more famous, privately held peer. Rocket Lab and SpaceX operate in the same commercial space sector but differ significantly in scale, maturity, and valuation. Rocket Lab's market cap is currently $12.85bn, with trailing 12 months (TTM) revenue of approximately $460m. Despite strong growth — revenue nearly doubled from $240m in 2023 — Rocket Lab remains a smaller, earlier-stage player focused on small to medium launch vehicles and spacecraft manufacturing. Its valuation multiples are extremely high, with a forward price-to-sales ratio of 22.3 times, reflecting investor optimism. SpaceX, by contrast, is a far more mature private company valued at about $350bn. It's projected to generate $15.5bn in revenue in 2025. This is driven by its dominant Falcon 9 launch services and rapidly growing Starlink satellite internet business. SpaceX's valuation implies roughly a 22.5 times multiple on forward revenue. This is broadly in line with Rocket Lab. Focusing on Rocket Lab, the company is projected to deliver rapid revenue growth over the next several years, with estimates rising from $573m in 2025 to $889 in 2026, $1.2bn in 2027, and $1.69bn in 2028. This represents annual growth rates consistently above 30%, and even a jump of nearly 77% in 2030. However, the number of analysts providing forecasts declines sharply after 2027, dropping from 11–14 analysts in the near term to just two or one by 2028 and 2030. The one analyst projecting as far as 2030 sees $4bn in revenue for the year. I had the chance to buy Rocket Lab shares at $15 just two months ago. I missed out as unfortunately my attention had been diverted elsewhere. However, I found another entry point. And personally, I see this as an investment to hold for a very long period. The space industry is still in its early innings, with enormous potential as satellite launches, lunar missions, and in-orbit services become increasingly mainstream. And like any investment, there are risks. Rocket Lab remains loss-making. It's expected to turn a profit in 2026, when it will trade at 620 times earnings. And while this moderates to 140 times in 2027, it's still expensive and introduces plenty of execution risk. However, I certainly believe UK investors should consider this one. It could be a real winner going forward. The post Investors should consider this growth stock… it's SpaceX's competition appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool James Fox has positions in Rocket Lab. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Sign in to access your portfolio
Yahoo
37 minutes ago
- Yahoo
Forget 'biological age' tests — longevity experts are using an $800 under-the-radar blood test to measure aging in real-time
Doctors and scientists are using a blood plasma test to study longevity. The test measures proteins and can tell you about your organ health. This field of proteomics could one day help detect diseases like cancer before they start. Should you have that second cup of coffee? How about a little wine with dinner? And, is yogurt really your superfood? Scientists are getting closer to offering consumers a blood test that could help people make daily decisions about how to eat, drink, and sleep that are more perfectly tailored to their unique biology. The forthcoming tests could also help shape what are arguably far more important health decisions, assessing whether your brain is aging too fast, if your kidneys are OK, or if that supplement or drug you're taking is actually doing any good. It's called an organ age test, more officially (and scientifically) known as "proteomics" — and it's the next hot "biological age" marker that researchers are arguing could be better than all the rest. "If I could just get one clock right now, I'd want to get that clock, and I'd like to see it clinically available in older adults," cardiologist Eric Topol, author of the recent bestseller "Super Agers: An Evidence-Based Approach to Longevity," told Business Insider. Topol said armed with organ age test results, people could become more proactive stewards of their own health, before it's too late. "When we have all these layers of data, it's a whole new day for preventing the disease," Topol said. "You see the relationship with women's hormones. You see the relationship with food and alcohol. You don't ever get that with genes." A test like this isn't available to consumers just yet, but it's already being used by researchers at elite universities and high-end longevity clinics. They hope it can become a tool any doctor could use to assess patient health in the next few years. A startup called Vero, which was spun out of some foundational proteomics research at Stanford University, is hoping to beta test a proteomics product for consumers this year. "Knowing your oldest organ isn't the point; changing the trajectory is," Vero co-founder and CEO Paul Coletta told a crowd gathered at the Near Future Summit in Malibu, California, last month. Coletta told Business Insider Vero's not interested in doing "wealthcare." The company plans to make its test available to consumers for around $200 a pop, at scale. Their draw only requires one vial of blood. The big promise of proteomics is that it could be a more precise real-time tool for tracking important but subtle changes that emerge inside each of us as we age. Genetic testing can measure how our bodies are built, spotting vulnerabilities in a person's DNA that might predispose them to health issues. Standard clinical measurements like a person's weight, blood pressure, or cholesterol readings are a useful proxy for potential health issues. Then there are the increasingly popular "biological age" tests available to consumers at home. Most of those look at "epigenetic changes" — how environmental factors affect our gene expression. Proteomics does something different and new. It measures the product that our bodies make based on all those genetic and environmental inputs: proteins. It offers a live assessment of how your body is running, not just how it's programmed. If validated in the next few years, these tests could become key in early disease detection and prevention. They could help influence all kinds of medical decisions, from big ones like "What drugs should I take?" to little ones like "How does my body respond to caffeine or alcohol?" Some high-end longevity clinics are already forging ahead using proteomics to guide clinical recommendations, albeit cautiously. Dr. Evelyne Bischof, a longevity physician who treats patients worldwide, said she uses proteomic information to guide some of the lifestyle interventions she recommends to her patients. She may suggest a more polyphenol-rich diet to someone who seems to have high inflammation and neuroinflammation based on proteomic test results, or may even suggest they do a little more cognitive training, based on what proteomics says about how their brain is aging. Dr. Andrea Maier, a professor of medicine and functional aging at the National University of Singapore, told BI she uses this measurement all the time in her longevity clinics. For her, it's just a research tool, but if the results of her ongoing studies are decent, she hopes to be able to use it clinically in a few years' time. "We want to know what kind of 'ageotype' a person is, so what type of aging personality are you, not from a mental perspective, but from a physical perspective," Maier said. "It's really discovery at this moment in time, and at the edge of being clinically meaningful." "Once we have that validated tool, we will just add it to our routine testing and we can just tick the box and say, 'I also want to know if this person is a cardiac ager, or a brain ager, or a muscle ager' because now we have a sensitive parameter — protein — which can be added," Maier said. The two big-name proteomics tests are Olink and SOMAscan. For now, their high-end screening costs around $400-$800 per patient. "I'm losing lots of money at the moment because of proteomics for clinical research!" Maier said. Top aging researchers at Stanford and Harvard are pushing the field forward, racing to publish more novel insights about the human proteome. The latest findings from Harvard aging researcher Vadim Gladyshev's lab, published earlier this year, suggest that as we age, each person may even stand to benefit from a slightly different antiaging grocery list. To research this idea, Gladyshev looked at proteins in the blood of more than 50,000 people in the UK, all participants in the UK Biobank who are being regularly tested and studied to learn more about their long-term health. He tracked their daily habits and self-reported routines like diet, occupation, and prescriptions, comparing those details to how each patient's organs were aging. He discovered some surprising connections. Yogurt eating, generally speaking, tended to be associated with better intestinal aging but had relatively no benefit to the arteries. White wine drinking, on the other hand, seemed to potentially confer some small benefit to the arteries while wreaking havoc on the gut. "The main point is that people age in different ways in different organs, and therefore we need to find personalized interventions that would fit that particular person," Gladyshev told BI. "Through measuring proteins, you assess the age of different organs and you say, 'OK, this person is old in this artery.'" For now, there's too much noise in the data to do more. Dr. Pal Pacher, a senior investigator at the National Institute on Alcohol Abuse and Alcoholism who studies organ aging and injuries, told BI that proteomics is simply not ready for clinical use yet. There's just too much noise in the data. But he imagines a future where a more sophisticated protein clock could help link up which people may be most vulnerable to diseases like early cancer, kidney disease, and more. (A California-based proteomics company called Seer announced last weekend that it is partnering with Korea University to study whether proteomics can help more quickly diagnose cancer in young people in their 20s and 30s.) "How beautiful could it be in the future?" Maier said. "Instead of three hours of clinical investigation, I would have a tool which guides me much, much better, with more validity towards interventions." Read the original article on Business Insider
